{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:38:22Z","timestamp":1780591102181,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T00:00:00Z","timestamp":1512604800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40264-017-0621-3","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T11:18:39Z","timestamp":1512645519000},"page":"347-356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Management Strategies to Facilitate Optimal Outcomes for Patients Treated with Delayed-release Dimethyl Fumarate"],"prefix":"10.1007","volume":"41","author":[{"given":"Lori","family":"Mayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Kay","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Sammarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Laing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,7]]},"reference":[{"issue":"1\u20132","key":"621_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S0165-5728(99)00193-9","volume":"100","author":"A Bar-Or","year":"1999","unstructured":"Bar-Or A, Oliveira EM, Anderson DE, Hafler DA. Molecular pathogenesis of multiple sclerosis. J Neuroimmunol. 1999;100(1\u20132):252\u20139. https:\/\/doi.org\/10.1016\/S0165-5728(99)00193-9 .","journal-title":"J Neuroimmunol."},{"issue":"1","key":"621_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neuron.2006.09.011","volume":"52","author":"SL Hauser","year":"2006","unstructured":"Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 2006;52(1):61\u201376. https:\/\/doi.org\/10.1016\/j.neuron.2006.09.011 .","journal-title":"Neuron."},{"key":"621_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.msard.2015.09.002","volume":"6","author":"DS Goodin","year":"2016","unstructured":"Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, et al. Relapses in multiple sclerosis: relationship to disability. Mult Scler Relat Disord. 2016;6:10\u201320. https:\/\/doi.org\/10.1016\/j.msard.2015.09.002 .","journal-title":"Mult Scler Relat Disord."},{"issue":"8","key":"621_CR4","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1177\/1352458507078393","volume":"13","author":"KV Turpin","year":"2007","unstructured":"Turpin KV, Carroll LJ, Cassidy JD, Hader WJ. Deterioration in the health-related quality of life of persons with multiple sclerosis: the possible warning signs. Mult Scler J. 2007;13(8):1038\u201345. https:\/\/doi.org\/10.1177\/1352458507078393 .","journal-title":"Mult Scler J."},{"issue":"1","key":"621_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1468-1331.2010.03110.x","volume":"18","author":"V Devonshire","year":"2011","unstructured":"Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, et al. GAP Study Group. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18(1):69\u201377. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03110.x .","journal-title":"Eur J Neurol."},{"key":"621_CR6","unstructured":"Biogen. Tecfidera (dimethyl fumarate) delayed-release capsules: US prescribing information. 2017. https:\/\/www.tecfidera.com\/content\/dam\/commercial\/multiple-sclerosis\/tecfidera\/pat\/en_us\/pdf\/full-prescribing-info.pdf . Accessed\u00a022 November\u00a02017."},{"issue":"2","key":"621_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40265-015-0528-1","volume":"76","author":"ED Deeks","year":"2016","unstructured":"Deeks ED. Dimethyl fumarate: a review in relapsing-remitting MS. Drugs. 2016;76(2):243\u201354. https:\/\/doi.org\/10.1007\/s40265-015-0528-1 .","journal-title":"Drugs."},{"issue":"4","key":"621_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11910-016-0639-4","volume":"16","author":"B Kretzschmar","year":"2016","unstructured":"Kretzschmar B, Pellkofer H, Weber MS. The use of oral disease-modifying therapies in multiple sclerosis. Curr Neurol Neurosci Rep. 2016;16(4):38. https:\/\/doi.org\/10.1007\/s11910-016-0639-4 .","journal-title":"Curr Neurol Neurosci Rep."},{"key":"621_CR9","unstructured":"Biogen. Tecfidera gastro-resistant hard capsules: EU summary of product characteristics. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002601\/WC500162069.pdf . Accessed\u00a022\u00a0Nov\u00a02017."},{"issue":"1","key":"621_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3988\/jcn.2015.11.1.9","volume":"11","author":"W Kim","year":"2015","unstructured":"Kim W, Zandon\u00e1 ME, Kim SH, Kim HJ. Oral disease-modifying therapies for multiple sclerosis. J Clin Neurol. 2015;11(1):9\u201319. https:\/\/doi.org\/10.3988\/jcn.2015.11.1.9 .","journal-title":"J Clin Neurol."},{"issue":"12","key":"621_CR11","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.clinthera.2014.08.013","volume":"36","author":"M Kita","year":"2014","unstructured":"Kita M, Fox RJ, Gold R, Giovannoni G, Phillips JT, Sarda SP, et al. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies. Clin Ther. 2014;36(12):1958\u201371. https:\/\/doi.org\/10.1016\/j.clinthera.2014.08.013 .","journal-title":"Clin Ther."},{"issue":"2","key":"621_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1185\/03007995.2013.849236","volume":"30","author":"RJ Fox","year":"2014","unstructured":"Fox RJ, Kita M, Cohan SL, Henson LJ, Zambrano J, Scannevin RH, et al. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr Med Res Opin. 2014;30(2):251\u201362. https:\/\/doi.org\/10.1185\/03007995.2013.849236 .","journal-title":"Curr Med Res Opin."},{"issue":"12","key":"621_CR13","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. CONFIRM Study Group. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1206328 .","journal-title":"N Engl J Med."},{"issue":"12","key":"621_CR14","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. DEFINE Study Group. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1114287 .","journal-title":"N Engl J Med."},{"issue":"2","key":"621_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/acn3.148","volume":"2","author":"V Viglietta","year":"2015","unstructured":"Viglietta V, Miller D, Bar-Or A, Phillips JT, Arnold DL, Selmaj K, et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol. 2015;2(2):103\u201318. https:\/\/doi.org\/10.1002\/acn3.148 .","journal-title":"Ann Clin Transl Neurol."},{"issue":"2","key":"621_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/1352458516649037","volume":"23","author":"R Gold","year":"2016","unstructured":"Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. Mult Scler J. 2016;23(2):253\u201365. https:\/\/doi.org\/10.1177\/1352458516649037 .","journal-title":"Mult Scler J."},{"issue":"1","key":"621_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40120-016-0042-8","volume":"5","author":"R Gold","year":"2016","unstructured":"Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Marantz JL. Sustained effect of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing\u2013remitting multiple sclerosis: 6-year interim results from an extension of the DEFINE and CONFIRM studies. Neurol Ther. 2016;5(1):45\u201357. https:\/\/doi.org\/10.1007\/s40120-016-0042-8 .","journal-title":"Neurol Ther."},{"key":"621_CR18","doi-asserted-by":"crossref","unstructured":"Gold R, Giovannoni G, Phillips JT, Fox RJ, Xiao J, Taylor C et al. Seven-year follow-up of the efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: integrated analysis of DEFINE, CONFIRM and ENDORSE (Abstract: P631). Presented at: 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, London, UK, 14\u201317 September 2016.","DOI":"10.26226\/morressier.59a3eda8d462b8028d895222"},{"issue":"2","key":"621_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/03007995.2016.1248380","volume":"33","author":"RJ Fox","year":"2017","unstructured":"Fox RJ, Chan A, Zhang A, Xiao J, Levison D, Lewin JB, et al. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis. Curr Med Res Opin. 2017;33(2):175\u201383. https:\/\/doi.org\/10.1080\/03007995.2016.1248380 .","journal-title":"Curr Med Res Opin."},{"issue":"Suppl 3","key":"621_CR20","first-page":"298","volume":"22","author":"T Berger","year":"2016","unstructured":"Berger T, Brochet B, Confalonieri P, Giacomini P, Montalban X, Vasco Salgado A, et al. Effectiveness of delayed-release dimethyl fumarate on clinical disease activity and patient-reported outcomes in patients with relapsing-remitting multiple sclerosis in the real-world setting: a multicentre, open-label study (PROTEC). Mult Scler J. 2016;22(Suppl 3):298.","journal-title":"Mult Scler J."},{"issue":"Suppl 3","key":"621_CR21","first-page":"775","volume":"22","author":"N Everage","year":"2016","unstructured":"Everage N, Prada C, Liu S, Balashov K, Macdonell R, Windsheimer J, et al. Delayed-release dimethyl fumarate in multiple sclerosis patients treated in routine medical practice: the first interim analysis of ESTEEM. Mult Scler J. 2016;22(Suppl 3):775\u20136.","journal-title":"Mult Scler J."},{"issue":"Suppl 3","key":"621_CR22","first-page":"774","volume":"22","author":"K Kresa-Reahl","year":"2016","unstructured":"Kresa-Reahl K, Repovic P, Robertson D, Okwuokenye M, Meltzer L, Mendoza J. Clinical measures and impact on patient-reported outcomes of delayed-release dimethyl fumarate in relapsing multiple sclerosis patients after suboptimal response to glatiramer acetate: analysis of the 12-month RESPOND study. Mult Scler J. 2016;22(Suppl 3):774.","journal-title":"Mult Scler J."},{"issue":"1","key":"621_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7224\/1537-2073.2014-101","volume":"18","author":"EJ Fox","year":"2016","unstructured":"Fox EJ, Vasquez A, Grainger W, Ma TS, von Hehn C, Walsh J, et al. Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE). Int J MS Care. 2016;18(1):9\u201318. https:\/\/doi.org\/10.7224\/1537-2073.2014-101 .","journal-title":"Int J MS Care."},{"issue":"2","key":"621_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40120-015-0037-x","volume":"4","author":"JT Phillips","year":"2015","unstructured":"Phillips JT, Erwin AA, Agrella S, Kremenchutzky M, Kramer JF, Darkes MJ, et al. Consensus management of gastrointestinal events associated with delayed-release dimethyl fumarate: a Delphi study. Neurol Ther. 2015;4(2):137\u201346. https:\/\/doi.org\/10.1007\/s40120-015-0037-x .","journal-title":"Neurol Ther."},{"issue":"14 Supplement","key":"621_CR25","doi-asserted-by":"crossref","first-page":"P3.242","DOI":"10.1212\/WNL.84.14_supplement.P3.242","volume":"84","author":"JT Phillips","year":"2015","unstructured":"Phillips JT, Erwin A, Agrella S, Kremenchutzky M, Kramer J, Kendter J, et al. Results of a Delphi panel to address management of gastrointestinal side effects observed with use of delayed-release dimethyl fumarate. Neurology. 2015;84(14 Suppl):P3.242.","journal-title":"Neurology."},{"issue":"4","key":"621_CR26","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.msard.2014.03.003","volume":"3","author":"JT Phillips","year":"2014","unstructured":"Phillips JT, Hutchinson M, Fox R, Gold R, Havrdova E. Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: experiences of an international panel. Mult Scler Relat Disord. 2014;3(4):513\u20139. https:\/\/doi.org\/10.1016\/j.msard.2014.03.003 .","journal-title":"Mult Scler Relat Disord."},{"issue":"Suppl 1","key":"621_CR27","first-page":"90","volume":"20","author":"C Tornatore","year":"2014","unstructured":"Tornatore C, Li J, Ma T, von Hehn C, Walsh J, Zambrano J. Effect of bismuth subsalicylate on gastrointestinal events associated with delayed-release dimethyl fumarate: a double-blind, placebo-controlled study. Mult Scler J. 2014;20(Suppl 1):90.","journal-title":"Mult Scler J."},{"key":"621_CR28","unstructured":"Tornatore C, Amjad F. Attenuation of dimethyl fumarate-related gastrointestinal symptoms with montelukast. Presented at: 66th American Academy of Neurology Annual Meeting, Philadelphia, PA, 26 April\u20133 May 2014."},{"issue":"7","key":"621_CR29","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.clinthera.2015.03.028","volume":"37","author":"J O\u2019Gorman","year":"2015","unstructured":"O\u2019Gorman J, Russell HK, Li J, Phillips G, Kurukulasuriya NC, Viglietta V. Effect of aspirin pretreatment or slow dose titration on flushing and gastrointestinal events in healthy volunteers receiving delayed-release dimethyl fumarate. Clin Ther. 2015;37(7):1402\u201319. https:\/\/doi.org\/10.1016\/j.clinthera.2015.03.028 .","journal-title":"Clin Ther."},{"issue":"Suppl 1","key":"621_CR30","first-page":"206","volume":"20","author":"C Sammarco","year":"2014","unstructured":"Sammarco C, Laing L, Herbert J. Strategies to reduce adverse events related to oral dimethyl fumarate. Mult Scler J. 2014;20(Suppl 1):206.","journal-title":"Mult Scler J."},{"issue":"Suppl 1","key":"621_CR31","first-page":"203","volume":"20","author":"M M\u00e4urer","year":"2014","unstructured":"M\u00e4urer M, Voltz R, Begus-Nahrmann Y, Schmid B, Niemczyk G, Kieseier BC. Adherence project with German MS-patients: can an approach of individualized patient counseling improve adherence? Mult Scler J. 2014;20(Suppl 1):203.","journal-title":"Mult Scler J."},{"issue":"Suppl 1","key":"621_CR32","first-page":"57","volume":"17","author":"JT Phillips","year":"2015","unstructured":"Phillips JT, Erwin A, Agrella S, Kremenchutzky M, Kramer J, Kendter J, et al. Use of a Delphi process to gain consensus on effective management of gastrointestinal side effects associated with extended-release dimethyl fumarate. Int J MS Care. 2015;17(Suppl 1):57\u20138.","journal-title":"Int J MS Care."},{"issue":"2","key":"621_CR33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7224\/1537-2073.2015-086","volume":"19","author":"JT Phillips","year":"2017","unstructured":"Phillips JT, Agrella S, Fox RJ. Dimethyl fumarate: a review of efficacy and practical management strategies for common adverse events in patients with multiple sclerosis. Int J MS Care. 2017;19(2):74\u201383.","journal-title":"Int J MS Care"},{"key":"621_CR34","unstructured":"Walgreens. 2017. http:\/\/www.walgreens.com . Accessed 17 Oct 2017."},{"key":"621_CR35","unstructured":"Drugs.com. 2017. http:\/\/www.drugs.com . Accessed 17 Oct 2017."},{"key":"621_CR36","unstructured":"Mayo Clinic. Who should consider calcium supplements? 2017. https:\/\/www.mayoclinic.org\/healthy-lifestyle\/nutrition-and-healthy-eating\/in-depth\/calcium-supplements\/art-20047097?pg=2 . Accessed 17 Oct 2017."},{"key":"621_CR37","unstructured":"Zantac tablets, dispersible tablets, effervescent tablets, syrup, and injection product information. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2013-PI-01042-1&d=2017101716114622483 . Accessed 17 Oct 2017."},{"issue":"Suppl 3","key":"621_CR38","first-page":"877","volume":"22","author":"R Gold","year":"2016","unstructured":"Gold R, Schlegel E, Elias-Hamp B, Albert C, Schmidt S, Tackenberg B, et al. Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving dimethyl fumarate: a German phase IV study (TOLERATE). Mult Scler J. 2016;22(Suppl 3):877.","journal-title":"Mult Scler J."},{"issue":"5","key":"621_CR39","doi-asserted-by":"publisher","first-page":"236","DOI":"10.7224\/1537-2073.2014-069","volume":"17","author":"JT Phillips","year":"2015","unstructured":"Phillips JT, Selmaj K, Gold R, Fox RJ, Havrdova E, Giovannoni G, et al. Clinical significance of gastrointestinal and flushing events in patients with multiple sclerosis treated with delayed-release dimethyl fumarate. Int J MS Care. 2015;17(5):236\u201343. https:\/\/doi.org\/10.7224\/1537-2073.2014-069 .","journal-title":"Int J MS Care."},{"key":"621_CR40","unstructured":"National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health. Common terminology criteria for adverse events, version 4.0. 2010. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf . Accessed 10 Nov 2016."},{"issue":"16 Suppl","key":"621_CR41","doi-asserted-by":"crossref","first-page":"Suppl P2.099","DOI":"10.1212\/WNL.86.16_supplement.P2.099","volume":"86","author":"RJ Fox","year":"2016","unstructured":"Fox RJ, Chan A, Gold R, Phillips JT, Selmaj K, Zhang R, et al. Characterization of absolute lymphocyte count profiles in MS patients treated with delayed-release dimethyl fumarate: considerations for patient management. Neurology. 2016;86(16 Suppl): P2.099.","journal-title":"Neurology."},{"issue":"15","key":"621_CR42","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1056\/NEJMc1415408","volume":"372","author":"T Rosenkranz","year":"2015","unstructured":"Rosenkranz T, Novas M, Terborg C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med. 2015;372(15):1476\u20138. https:\/\/doi.org\/10.1056\/NEJMc1415408 .","journal-title":"N Engl J Med."},{"key":"621_CR43","unstructured":"Biogen Inc. Biogen Medical Information Web Site. 2017. https:\/\/www.tecfidera.com\/content\/dam\/commercial\/multiple-sclerosis\/tecfidera\/pat\/en_us\/pdf\/full-prescribing-info.pdf . Accessed 21 April 2017."},{"key":"621_CR44","unstructured":"Mayer L, Fox EJ, Vasquez A, Grainger W, Ma T, von Hehn C et al. Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE). In: 47th Annual Meeting of the American Association of Neuroscience Nurses, Nashville, TN, 29 March\u20131 April 2015."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-017-0621-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0621-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0621-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T14:21:45Z","timestamp":1719670905000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-017-0621-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,7]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["621"],"URL":"https:\/\/doi.org\/10.1007\/s40264-017-0621-3","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,7]]}}}